Femring is a drug owned by Millicent Holdings Ltd. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 19, 2015. Details of Femring's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5855906 | Intravaginal drug delivery devices for the administration of 17β-oestradiol precursors |
Dec, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Femring is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Femring's family patents as well as insights into ongoing legal events on those patents.
Femring's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Femring's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 19, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Femring Generics:
There are no approved generic versions for Femring as of now.
Alternative Brands for Femring
Femring which is used for long-term hormone replacement therapy in women., has several other brand drugs using the same active ingredient (Estradiol Acetate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Apil |
|
About Femring
Femring is a drug owned by Millicent Holdings Ltd. It is used for long-term hormone replacement therapy in women. Femring uses Estradiol Acetate as an active ingredient. Femring was launched by Millicent in 2003.
Approval Date:
Femring was approved by FDA for market use on 20 March, 2003.
Active Ingredient:
Femring uses Estradiol Acetate as the active ingredient. Check out other Drugs and Companies using Estradiol Acetate ingredient
Treatment:
Femring is used for long-term hormone replacement therapy in women.
Dosage:
Femring is available in insert, extended release form for vaginal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.05MG BASE/24HR | INSERT, EXTENDED RELEASE | Prescription | VAGINAL |
| EQ 0.1MG BASE/24HR | INSERT, EXTENDED RELEASE | Prescription | VAGINAL |